GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial. The headline ...
GSK (GSK) announced that the China National Medical Products Administration has approved Nucala, a monoclonal antibody that targets interleukin-5, as an add-on therapy with intranasal ...
Sanofi and Regeneron’s Dupixent has had the US market for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) mainly to itself since June 2019, but GlaxoSmithKline’s Nucala is ...
Hosted on MSN1mon
FDA to review GSK’s Nucala for COPDThe US Food and Drug Administration (FDA) has accepted a submission from GSK to review a new indication of Nucala (mepolizumab) as an add-on maintenance treatment for chronic obstructive pulmonary ...
GlobalData on MSN19d
China’s NMPA approves GSK’s Nucala for CRSwNP treatmentThe China National Medical Products Administration (NMPA) has approved GSK’s Nucala (mepolizumab) as an add-on treatment with intranasal corticosteroids to treat chronic rhinosinusitis with nasal ...
GSK plc announced that the China National Medical Products Administration (NMPA) has approved Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), as an add-on therapy with ...
GSK plans five new product approvals by 2025, highlights strong specialty growth, and acquires IDRx for $1 billion to expand its oncology portfolio.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback